Santhera submits nda in south korea for raxone® for the treatment of lhon – odessa american business database blob

Santhera Pharmaceuticals Holding AG / Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Pratteln, Switzerland, June 12, 2018 – Santhera Pharmaceuticals (SIX: SANN) announces that the Korean Ministry of Food and Drug Safety (MFDS) has accepted for review Santhera’s new drug application (NDA) for Raxone® (idebenone) for the treatment of Leber’s hereditary optic neuropathy (LHON). Raxone was granted orphan drug designation for LHON in South Korea.Raxone® (idebenone) is an oral medication, currently authorized in the European Union, Norway, Iceland, Liechtenstein and Israel at a daily dose of 900 mg for the treatment of visual impairment in adolescent and adult patients with LHON.


It is the first and only medicine approved for this rare inherited disease which, if untreated, invariably leads to profound vision loss and blindness. The NDA now submitted to the MFDS was prepared on the basis of the European marketing authorization and Santhera expects a decision from the South Korean drug regulatory authorities in approximately one year. "The regulatory submission of Raxone for LHON in South Korea, one of the major Asian markets, underlines our geographical expansion and our commitment to providing treatment to patients worldwide, addressing a major unmet medical need in this rare disease," said Thomas Meier, PhD, CEO of Santhera. Raxone has also been granted orphan drug designation for LHON in South Korea, which provides up to 10 years market exclusivity from the date of approval.About Leber’s Hereditary Optic Neuropathy and the Therapeutic Use of RaxoneLeber’s hereditary optic neuropathy (LHON) is a heritable genetic disease causing profound vision loss and blindness. The disease presents predominantly in young, otherwise healthy adult males as rapid, painless loss of central vision, usually leading to permanent bilateral blindness within a few months of the onset of symptoms. About 95% of patients harbor one of three pathogenic mutations of the mitochondrial DNA, which cause a defect in the complex I subunit of the mitochondrial respiratory chain. This defect leads to decreased cellular energy (ATP) production, increased reactive oxygen species (ROS) production and retinal ganglion cell dysfunction, which cause progressive loss of visual acuity and blindness. Raxone (idebenone), a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1), circumvents the complex I defect, reduces and scavenges ROS, restores cellular energy levels in retinal ganglion cells and promotes recovery of visual acuity. Current data demonstrate that up to 50% of patients benefit from treatment and are protected from progression of visual acuity loss or experience a clinically relevant recovery of visual acuity. Raxone for the treatment of LHON was granted orphan drug status in the EU, US, Switzerland and South Korea.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for orphan and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. The most advanced pipeline product, idebenone, is in clinical Phase III for the treatment of Duchenne muscular dystrophy (DMD). Santhera’s Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber’s hereditary optic neuropathy (LHON) and currently commercialized in more than 20 countries. For further information, please visit www.santhera.com.Raxone® is a trademark of Santhera Pharmaceuticals.For further information please contact: public-relations@santhera.com or Eva Kalias, Head External Communications Phone: +41 79 875 27 80 eva.kalias@santhera.comFor Investors: investor-relations@santhera.com or Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors Europe: +41 61 906 89 65 US: +1 212 915 2568 christoph.rentsch@santhera.com hans@lifesciadvisors.comDisclaimer / Forward-looking statementsThis communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

banner